These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 38672662)

  • 1. T-Cell Engagers-The Structure and Functional Principle and Application in Hematological Malignancies.
    Cech P; Skórka K; Dziki L; Giannopoulos K
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
    Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
    J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are BiTEs the "missing link" in cancer therapy?
    Suryadevara CM; Gedeon PC; Sanchez-Perez L; Verla T; Alvarez-Breckenridge C; Choi BD; Fecci PE; Sampson JH
    Oncoimmunology; 2015 Jun; 4(6):e1008339. PubMed ID: 26155413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redirecting T cells to hematological malignancies with bispecific antibodies.
    Velasquez MP; Bonifant CL; Gottschalk S
    Blood; 2018 Jan; 131(1):30-38. PubMed ID: 29118005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
    Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.
    Baeuerle PA; Wesche H
    Curr Opin Oncol; 2022 Sep; 34(5):552-558. PubMed ID: 35880455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T Cell Receptor-Directed Bispecific T Cell Engager Targeting MHC-Linked NY-ESO-1 for Tumor Immunotherapy.
    Li Y; Zhao W; Shen Y; Xu Y; Chen S; Pan L
    Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
    Crupi MJF; Taha Z; Janssen TJA; Petryk J; Boulton S; Alluqmani N; Jirovec A; Kassas O; Khan ST; Vallati S; Lee E; Huang BZ; Huh M; Pikor L; He X; Marius R; Austin B; Duong J; Pelin A; Neault S; Azad T; Breitbach CJ; Stojdl DF; Burgess MF; McComb S; Auer R; Diallo JS; Ilkow CS; Bell JC
    Front Immunol; 2022; 13():1029269. PubMed ID: 36405739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
    Tian Z; Liu M; Zhang Y; Wang X
    J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of T-cell engagers selective for cells co-expressing two antigens.
    Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
    MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.
    Hays P
    Cancer Treat Res; 2022; 183():287-315. PubMed ID: 35551665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
    Friedrich MJ; Neri P; Kehl N; Michel J; Steiger S; Kilian M; Leblay N; Maity R; Sankowski R; Lee H; Barakat E; Ahn S; Weinhold N; Rippe K; Bunse L; Platten M; Goldschmidt H; Müller-Tidow C; Raab MS; Bahlis NJ
    Cancer Cell; 2023 Apr; 41(4):711-725.e6. PubMed ID: 36898378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
    Long M; Mims AS; Li Z
    Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bispecific antibodies targeting CD3 in oncology and hematology].
    Vanacker H; Vinceneux A; Nicolas-Virelizier E; Brahmi M; Cassier PA
    Bull Cancer; 2021 Oct; 108(10S):S181-S194. PubMed ID: 34920802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.
    Yoneyama T; Kim MS; Piatkov K; Wang H; Zhu AZX
    PLoS Comput Biol; 2022 Jul; 18(7):e1009715. PubMed ID: 35839267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
    Einsele H; Borghaei H; Orlowski RZ; Subklewe M; Roboz GJ; Zugmaier G; Kufer P; Iskander K; Kantarjian HM
    Cancer; 2020 Jul; 126(14):3192-3201. PubMed ID: 32401342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
    Stieglmaier J; Benjamin J; Nagorsen D
    Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.
    Nagorsen D; Bargou R; Ruttinger D; Kufer P; Baeuerle PA; Zugmaier G
    Leuk Lymphoma; 2009 Jun; 50(6):886-91. PubMed ID: 19455460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.